Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors-Reference-Cited by-同舟云学术

Proteomic Changes in the Monolayer and Spheroid Melanoma Cell Models of Acquired Resistance to BRAF and MEK1/2 Inhibitors

Published:2022-01-18 Issue:4 Volume:7 Page:3293-3311
ISSN:2470-1343
Container-title:ACS Omega
language:en
Short-container-title:ACS Omega

Author:

Martinez Ramon¹^ORCID,Huang Weiliang¹,Buck Heather²,Rea Samantha²,Defnet Amy E.¹,Kane Maureen A.¹^ORCID,Shapiro Paul¹

Affiliation:

1. Department of Pharmaceutical Sciences, University of Maryland School of Pharmacy, 20 Penn Street, Baltimore, Maryland 21201, United States

2. Nathan Schnaper Internship Program in Translational Cancer Research, Marlene and Stewart Greenebaum Comprehensive Cancer Center, University of Maryland School of Medicine, 22S. Greene Street, Baltimore, Maryland 21201, United States

Funder

National Center for Advancing Translational Sciences

National Institute of General Medical Sciences

Institute for Clinical and Translational Research, University of Maryland, Baltimore County

Publisher

American Chemical Society (ACS)

Subject

General Chemical Engineering,General Chemistry

Link

https://pubs.acs.org/doi/pdf/10.1021/acsomega.1c05361

Reference164 articles.

1. Ras-MAP Kinase Signaling Pathways and Control of Cell Proliferation: Relevance to Cancer Therapy

2. Signal Transduction through MAP Kinase Cascades

3. The MEK/ERK cascade: From signaling specificity to diverse functions

4. Regulatory Mechanisms and Function of ERK MAP Kinases

5. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Patient-derived melanoma models;Pathology - Research and Practice;2024-07

2. Bridging the gap between testing and clinics exploring alternative pre-clinical models in melanoma research;Advanced Drug Delivery Reviews;2024-05

3. Effects of MAPK pathway inhibitors (AZD6244) on resistance of breast cancer cells to chemotherapy and targeted therapy;Materials Express;2023-01-01

4. A multi-omics analysis of glioma chemoresistance using a hybrid microphysiological model of glioblastoma;2022-10-31

5. Targeting mitochondrial metabolism for metastatic cancer therapy;Molecular Carcinogenesis;2022-06-20